米氮平合并认知行为疗法治疗躯体形式障碍的疗效

The Efficacy of Mirtazapine Combined with Cognitive Behavior Therapy in Somatoform Disorder

目的：探讨米氮平合并认知行为疗法治疗躯体形式障碍的疗效。方法：将68例躯体形式障碍患者,随机分为研究组和对照组。研究组采用米氮平合并认知行为疗法,对照组单用米氮平治疗,疗程16周。采用症状自评量表（SCL-90）评估两组的疗效。结果：治疗16周末研究组SCL-90躯体化、抑郁、焦虑、恐怖因子分与对照组比较显著降低,差异有统计学意义（t=-2.26,-2.235,-2.15,-2.31;P〈0.05）。16周末研究组总有效率85.29%,对照组总有效率61.76%,研究组有效率高于对照组（χ^2=4.836,P〈0.05）,差异有统计学意义。结论：米氮平合并认知行为疗法治疗躯体形式障碍优于单用米氮平治疗。

Objective：To explore the clinical efficacy of cognitive behavior therapy（CBT）combined with mirtazapine in the treatment of somatoform disorder.Methods：68patients met the criteria of somatoform disorder in CCMD-3were randomly divided into study group treated with mirtazapine combined with CBT and control group treated with mirtazapine monotherapy for 16 weeks,The efficacy was assessed with symptom checklist-90（SCL-90）.Results：After 16 weeks treatment,the scores of somatization,depression,anxiety,phobia factors in the study group were significantly lower than those in the control group（P〈0.05）.The effective rate in study group was significantly higher than that in control group at the end of the treatment（85.29% vs.61.76%;χ^2=4.836,P〈0.05）.Conclusion：Mirtazapine combined with CBT is better than mirtazapine monotherapy in the treatment for somatoform disorder.